Visual Changes and Retinal Vein Occlusion and Macular Edema
common.study.values.description
“Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion”
The purpose of this study is to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Brolucizumab 6 mg
Solution for injection (intravitreal use)
Drug - Aflibercept 2 mg
Solution for injection (Intravitreal use)
Sham injection
Empty sterile syringe without a needle administered as a sham injection for masking
participant.views.study.view.additional
participant.views.study.view.scientific-title
An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
common.study.values.clinical-trial-id
NCT03810313
participant.views.study.view.id
e5yVZe
